Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 64HER2-positive Breast Cancer 11Carcinoma, Non-Small-Cell Lung 6HER2 Positive Metastatic Breast Cancer 4Breast Diseases 4Brain Neoplasms 4HER2 Positive Breast Cancer 3Advanced Breast Cancer 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2HER2-positive Metastatic Breast Cancer 2Colorectal Neoplasms 2Breast Cancer Invasive 2Breast Cancer Female 2Solid Tumor 1Salivary Gland Neoplasms 1Rare Tumour 1Rare Tumor 1Pathologic Complete Response 1Non-squamous NSCLC 1Non Small Cell Lung 1Neoplasm Metastasis 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1Metastatic Breast Cancer in the Brain 1Lung Neoplasms 1Locally Advanced Breast Cancer 1HER2-positive Early Breast Cancer 1HER2-expressing Advanced Solid Tumors 1HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1HER2+ Early or Locally Advanced Breast Cancer 1

Interventions

pembrolizumab 91Gemcitabine 55Nivolumab 49Cisplatin 38atezolizumab 31Carboplatin 30avelumab 25enfortumab vedotin 23Docetaxel 23Magnetic Resonance Spectroscopy 18Ipilimumab 17Paclitaxel 16Mitomycin 15Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Transitional Cell × pyrotinib × Clear all
NCT05318339 2022-04-08

A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma

ChineseAMS

Phase 2 Unknown
30 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡